Results 51 to 60 of about 29,725 (304)

Unraveling Caspofungin Resistance in Cryptococcus neoformans

open access: yesmBio, 2021
Cryptococcus neoformans is a basidiomycetous yeast responsible for hundreds of thousands of deaths a year and is particularly threatening in immunocompromised patients. There are few families of antifungals that are available to fight fungal infections, and the unique efficient treatment for the most deadly cerebral forms of ...
Papon, Nicolas, Goldman, Gustavo
openaire   +5 more sources

Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies [PDF]

open access: yes, 2015
Date of Acceptance: 23/07/2015 We thank Gillian Milne for help with electron microscopy, Sophie M. Schäfer for pilot experiments, and Emilia Mellado for strains. All authors acknowledge financial support of Gilead Sciences through Ph.D.
Gow, Neil A R   +3 more
core   +1 more source

Network Modeling Reveals Cross Talk of MAP Kinases during Adaptation to Caspofungin Stress in Aspergillus fumigatus. [PDF]

open access: yesPLoS ONE, 2015
Mitogen activated protein kinases (MAPKs) are highly conserved in eukaryotic organisms. In pathogenic fungi, their activities were assigned to different physiological functions including drug adaptation and resistance.
Robert Altwasser   +7 more
doaj   +1 more source

An on-line solid phase extraction procedure for the routine quantification of caspofungin by liquid chromatography-tandem mass spectrometry [PDF]

open access: yes, 2012
Background: Extensive sets of data are required to investigate the potential use of a therapeutic drug monitoring with individualization of dosage of the antimycotic compound caspofungin.
Kirchhoff, Fabian   +5 more
core   +1 more source

Disseminated candidemia refractory to caspofungin therapy in an infant with extremely low birth weight

open access: yesJournal of the Formosan Medical Association, 2012
Systemic fungal infections have high morbidity and mortality rates in neonates, especially neonates with an extremely low birth weight (ELBW). Here, we describe a 21-day-old ELBW female infant with an amphotericin B-unresponsive congenital Candida ...
Meng-Ju Li   +6 more
doaj   +1 more source

Caspofungin

open access: yesReactions weekly, 2020
An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component ...

semanticscholar   +1 more source

The Candida albicans transcription factor Cas5 couples stress responses, drug resistance and cell cycle regulation [PDF]

open access: yes, 2017
We thank Cowen lab members for helpful discussions. We also thank David Rogers (University of Tennessee) for sharing microarray analysis of the CAS5 homozygous mutant, and Li Ang (University of Macau) for assistance in optimizing the ChIP-Seq experiments.
Andrews, Brenda J   +18 more
core   +2 more sources

CASPOFUNGIN IN THE TREATMENT OF OROPHARYNGEAL CANDIDIASIS

open access: yesInternational Journal of Clinical Practice, 2003
SUMMARYA patient with AIDS developed oropharyngeal candidiasis. Candida albicans and C. glabrata were isolated from the patient and found to be resistant to fluconazole and itraconazole in vitro. Voriconazole therapy was initiated, but discontinued when the C. albicans strain isolated from the patient was found to be resistant to it. The patient failed
Garbino, Jorge   +3 more
openaire   +3 more sources

Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

open access: yesClinical Infectious Diseases, 2018
BACKGROUND Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis.
B. Kullberg   +18 more
semanticscholar   +1 more source

Caspofungin in the treatment of candidosis and aspergillosis

open access: yesInternational Journal of Infectious Diseases, 2003
Antifungal agents can be classified by their site of action in fungal cells, which can have important implications for both efficacy and tolerability. Currently available agents include the polyenes, nucleoside analogs, and the azoles. With the exception of 5-fluorocytosine, all agents act by interfering with the structural or functional integrity of ...
Johan Maertens, Marc Boogaerts
openaire   +3 more sources

Home - About - Disclaimer - Privacy